These omics data of the F-MPNs’ differentiation capacity were validated by quantitative reverse transcription PCR (qRT-PCR) on a larger cohort of F-MPN and control samples including samples used for RNA-Seq and ATAC-Seq (n = 10 and 12 F-MPN and control MSC samples), which showed an increased expression of osteoblast genes (ACTA2, PLZF1) and decreased expression of adipocyte gene (PPARγ) and chondrocyte gene (SOX9; Figure 2C). The gene discussed is ACTA2; the disease is myeloproliferative disorder.